Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia and overactive bladder: randomized controlled trial - Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for benign prostate hyperplasia with overactive bladder

Department of Urology, Kyorin University School of Medicine0 个研究点目标入组 200 人开始时间: 2015年3月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. patients who developed urinary retention in the past 12 months 2. patients who had post voiding residual volume 100mL or more 3. patients strongly suspected of prostate cancer 4. patients with indwelling urethral catheter or intermittent self-catheterization 5. patients with acute urinary tract infection 6. patients with nocturnal polyuria 7. patients with daily urine volume over 3000mL 8. patients with mechanical abnormality of lower urinary tract (eg. urethral stricture, bladder tumor and bladder stone) 9. patients without desire to void 10. patients with pyloric, duodenal or intestinal obstruction 11. patients with angle-closure glaucoma 12. patients with myasthenia gravis 13. patients with severe heart disease, renal dysfunction or liver dysfunction 14. patients with severe constipation 15. patients tadalafil and solifenacin is contraindicated 16. patients who have been determined to be unsuitable as a subject by a physician

发起方

Department of Urology, Kyorin University School of Medicine